- Home
- FTI vs UTHR Comparison
FTI vs UTHR Comparison
Compare FTI & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTI
- UTHR
- Stock Information
- Founded
- FTI 1884
- UTHR 1996
- Country
- FTI United States
- UTHR United States
- Employees
- FTI N/A
- UTHR N/A
- Industry
- FTI Metal Fabrications
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- FTI Industrials
- UTHR Health Care
- Exchange
- FTI Nasdaq
- UTHR Nasdaq
- Market Cap
- FTI 16.4B
- UTHR 13.8B
- IPO Year
- FTI N/A
- UTHR 1999
- Fundamental
- Price
- FTI $39.23
- UTHR $403.68
- Analyst Decision
- FTI Strong Buy
- UTHR Strong Buy
- Analyst Count
- FTI 13
- UTHR 15
- Target Price
- FTI $39.45
- UTHR $449.13
- AVG Volume (30 Days)
- FTI 7.6M
- UTHR 884.7K
- Earning Date
- FTI 10-23-2025
- UTHR 10-29-2025
- Dividend Yield
- FTI 0.51%
- UTHR N/A
- EPS Growth
- FTI 115.07
- UTHR 17.94
- EPS
- FTI 2.17
- UTHR 25.63
- Revenue
- FTI $9,504,100,000.00
- UTHR $3,077,800,000.00
- Revenue This Year
- FTI $9.81
- UTHR $13.89
- Revenue Next Year
- FTI $7.50
- UTHR $5.68
- P/E Ratio
- FTI $18.18
- UTHR $15.74
- Revenue Growth
- FTI 11.75
- UTHR 17.62
- 52 Week Low
- FTI $22.12
- UTHR $266.98
- 52 Week High
- FTI $41.30
- UTHR $436.95
- Technical
- Relative Strength Index (RSI)
- FTI 60.50
- UTHR 68.95
- Support Level
- FTI $38.60
- UTHR $396.12
- Resistance Level
- FTI $41.30
- UTHR $407.06
- Average True Range (ATR)
- FTI 1.02
- UTHR 13.53
- MACD
- FTI 0.00
- UTHR 2.19
- Stochastic Oscillator
- FTI 59.63
- UTHR 75.31
About FTI TechnipFMC plc
TechnipFMC is the largest provider of offshore oilfield services, offering integrated deep-water offshore oil and gas development solutions that span the full spectrum of subsea equipment and subsea construction services. The company also provides various pieces of surface equipment used with onshore oil and gas wells. TechnipFMC originated with the 2017 merger of Technip and FMC Technologies.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.